car-t

Addition to the Conditional Monge Gap to extend it to Chimeric Antigen Receptor T cell scRNAseq data

Files and code used to generate the CARTAR app to identify and validate CAR targets for cancer treatment.

Systematic pipeline for identifying combinatorial CAR-T targets in acute myeloid leukemia (AML) using single-cell RNA-seq data

Single-cell transcriptomic profiling of CAR T cells expressing synthetic receptors, termed "velocity CAR T" cells.

Files and code used to generate the CARTAR app to identify and validate CAR targets for cancer treatment.

Single-cell analysis of CAR T-cell therapy responses, identifying cellular signatures and pathways associated with treatment outcomes.

Interactive dashboard tracking CAR-T, CAR-NK, CAAR-T, and CAR-γδ T clinical trials across heme- and solid-onc from ClinicalTrials.gov v2. Sister app to Rheumatology-CAR-T-Trials-Monitor.

R analysis of xCELLigence real-time impedance killing assays for T/CAR-cell and NK cytotoxicity

Personalized lymphoma therapy design with Gemma 4, AlphaFold, RFdiffusion. Kaggle Gemma 4 Good Hackathon submission.

Autolus is a life-sciences (biopharmaceutical) company operating in the cell-therapy space, developing programmed / engineered T cell (CAR-T) therapies for cancer and other serious diseases. It was surfaced as a portfolio company of GV and added to the API Evangelist network for enrichment.

AbelZeta Pharma is a global clinical-stage cell therapy company discovering, developing, and manufacturing T-cell-based immunotherapeutics for cancer and immunological diseases. Its pipeline centers on Chimeric Antigen Receptor (CAR)-T cell technology across hematologic malignancies, solid tumors, and inflammatory and immunological conditions.

Cell Design Labs, Inc. was a biotherapeutics company based at 5858 Horton Street, Emeryville, California, that engineered immune cells into "smart, living therapies" for cancer and other diseases.

Kyverna Therapeutics (Nasdaq: KYTX) is a patient-centered, clinical-stage biopharmaceutical company headquartered in Emeryville, California, developing engineered T cell therapies for patients suffering from autoimmune diseases.

Stylus Medicine is a Cambridge, Massachusetts biotechnology company developing in vivo genetic medicines built on engineered recombinases. Its platform aims to generate precise, durable CAR-T cells directly inside the body using cell-targeted lipid nanoparticle delivery to immune cells, with therapeutic programs spanning oncology, autoimmune…

Orbital Therapeutics was a Cambridge, Massachusetts biotechnology company developing next-generation RNA medicines, combining circular and linear RNA, targeted delivery, and AI-guided design across immunomodulation, in vivo CAR-T cell therapy, next-generation vaccines, and protein therapeutics.

Oricell Therapeutics (原启生物) is a Shanghai-based clinical-stage biopharmaceutical company developing cell-based immunotherapies for cancer, including GPC3-targeted CAR-T (Ori-C101) for advanced liver cancer and GPRC5D-targeted CAR-T (OriCAR-017) for relapsed/refractory multiple myeloma.

Umoja Biopharma is a Seattle-based clinical-stage immuno-oncology company developing in vivo CAR T cell therapies for cancer. Its VivoVec lentiviral platform generates CAR T cells directly in a patient's body, removing the ex vivo manufacturing step of traditional cell therapy, and the company operates its own manufacturing facility in Louisville…

Using scRNA-seq, machine learning, and online datasets to find candidate target antigens for repurposing CAR T-cell therapy for autoimmune diseases.

Link Cell Therapies is a South San Francisco clinical-stage cell therapy company founded by Stanford investigators Robbie Majzner and Crystal Mackall in partnership with Samsara BioCapital, working on the development of safe and effective CAR T agents for patients with solid tumors.

Repository for analyses of HHV-6 reactivation using genomics